These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 35902033

  • 1. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM, Killian JM, Roger VL, Schulte PJ, Blecker SB, Savitz ST, Redfield MM.
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [Abstract] [Full Text] [Related]

  • 2. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ, Butler J, Hellkamp AS, Spertus JA, Vaduganathan M, Devore AD, Albert NM, Patterson JH, Thomas L, Williams FB, Hernandez AF, Fonarow GC.
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [Abstract] [Full Text] [Related]

  • 3. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W, ASIAN-HF investigators, Richards AM, Voors A, Lam CS.
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [Abstract] [Full Text] [Related]

  • 4. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B, Zhang R, Wu X, Zhou X.
    JAMA Netw Open; 2022 Sep 01; 5(9):e2231963. PubMed ID: 36125813
    [Abstract] [Full Text] [Related]

  • 5. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.
    Cox ZL, Zalawadiya SK, Simonato M, Redfors B, Zhou Z, Kotinkaduwa L, Zile MR, Udelson JE, Lim DS, Grayburn PA, Mack MJ, Abraham WT, Stone GW, Lindenfeld J.
    JACC Heart Fail; 2023 Jul 01; 11(7):791-805. PubMed ID: 37115135
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U, Ergin I, Kıvrak T, Yılmaz Öztekin GM, Tanık VO, Özdemir İ, Avcı Demir F, Doğduş M, Şen T, Altınsoy M, Üstündağ S, Urgun ÖD, Sinan ÜY, Uygur B, Yeni M, Özçalık E.
    ESC Heart Fail; 2023 Dec 01; 10(6):3677-3689. PubMed ID: 37804042
    [Abstract] [Full Text] [Related]

  • 7. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
    Vaduganathan M, Fonarow GC, Greene SJ, Devore AD, Albert NM, Duffy CI, Hill CL, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Butler J.
    J Card Fail; 2022 Feb 01; 28(2):191-201. PubMed ID: 34428591
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
    Smith KV, Dunning JR, Fischer CM, MacLean TE, Bosque-Hamilton JW, Fera LE, Grant JY, Zelle DJ, Matta L, Gaziano TA, MacRae CA, Scirica BM, Desai AS.
    J Pharm Pract; 2022 Oct 01; 35(5):747-751. PubMed ID: 33813934
    [Abstract] [Full Text] [Related]

  • 9. Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction.
    Mentz RJ, Lautsch D, Pulungan Z, Kim S, Hilkert R, Teigland C, Yang M, Djatche L.
    J Card Fail; 2022 Aug 01; 28(8):1349-1354. PubMed ID: 34930657
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    Sandhu AT, Kohsaka S, Turakhia MP, Lewis EF, Heidenreich PA.
    JAMA Cardiol; 2022 Feb 01; 7(2):130-139. PubMed ID: 34757380
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA).
    Rivera-Toquica A, Echeverría LE, Arias-Barrera CA, Mendoza-Beltrán F, Hoyos-Ballesteros DH, Plata-Mosquera CA, Ortega-Madariaga JC, Carvajal-Estupiñán JF, Quintero-Yepes V, Zárate-Correa LC, García-Peña ÁA, Velásquez-López N, Anchique CV, Saldarriaga CI, Gómez-Mesa JE.
    Cardiology; 2024 Feb 01; 149(3):228-236. PubMed ID: 38359813
    [Abstract] [Full Text] [Related]

  • 14. Impact of Individual Patient Profiles on Adherence to Guideline Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction: VCOR-HF Study.
    Driscoll A, Dinh D, Wong J, Hopper I, Mariani J, Zimmet H, Brennan A, Lefkovits J, Carruthers H, Reid CM.
    Heart Lung Circ; 2020 Dec 01; 29(12):1782-1789. PubMed ID: 32646638
    [Abstract] [Full Text] [Related]

  • 15. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK, Sharma K, Mittal S, Monteiro R, Libbus I, Ardell JL, Gregory DD, KenKnight BH, Amurthur B, DiCarlo LA, Anand IS.
    ESC Heart Fail; 2019 Oct 01; 6(5):1052-1056. PubMed ID: 31339232
    [Abstract] [Full Text] [Related]

  • 16. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
    Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Kavati A, Sikirica S, Albert NM, Duffy CI, Hill CL, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Butler J.
    JACC Heart Fail; 2020 Jun 01; 8(6):469-480. PubMed ID: 32387066
    [Abstract] [Full Text] [Related]

  • 17. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
    McCullough PA, Mehta HS, Barker CM, Van Houten J, Mollenkopf S, Gunnarsson C, Ryan M, Cork DP.
    Clin Cardiol; 2021 Sep 01; 44(9):1192-1198. PubMed ID: 34342033
    [Abstract] [Full Text] [Related]

  • 18. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
    Teng TK, Tay WT, Ouwerkerk W, Tromp J, Richards AM, Gamble G, Greene SJ, Yiu KH, Poppe K, Ling LH, Lund M, Sim D, Devlin G, Loh SY, Troughton R, Ren QW, Jaufeerally F, Lee SGS, Tan RS, Soon DKN, Leong G, Ong HY, Yeo DPS, Lam CSP, Doughty RN.
    ESC Heart Fail; 2023 Apr 01; 10(2):1280-1293. PubMed ID: 36722315
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD.
    Lancet; 2020 Jul 11; 396(10244):121-128. PubMed ID: 32446323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.